Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Condition(s):Breast NeoplasmsLast Updated:July 19, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Breast NeoplasmsLast Updated:July 19, 2016Completed
Condition(s):Lung CancerLast Updated:September 17, 2013Completed
Condition(s):Cervical Cancer Recurrent or Persistent; Palliative Treatment; Monoclonal Antibody in Cervical Cancer TreatmentLast Updated:April 14, 2015Completed
Condition(s):Pediatric CancerLast Updated:September 13, 2016Unknown status
Condition(s):Cervical CancerLast Updated:August 25, 2021Completed
Condition(s):Non-Small Cell Lung CancerLast Updated:December 6, 2022Active, not recruiting
Condition(s):Lung CancerLast Updated:March 8, 2011Completed
Condition(s):Head and Neck NeoplasmsLast Updated:November 2, 2020Withdrawn
Condition(s):Lung CancerLast Updated:December 19, 2013Unknown status
Condition(s):Non-Hodgkin’s Lymphoma; Hodgkin’s DiseaseLast Updated:January 8, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.